PCRX
Undervalued by 124.3% based on the discounted cash flow analysis.
Market cap | $1.41 Billion |
---|---|
Enterprise Value | $1.61 Billion |
Dividend Yield | $0.0 (0.0%) |
Earnings per Share | $1.32 |
Beta | 0.5 |
Outstanding Shares | 46,546,148 |
Avg 30 Day Volume | 996,056 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | 20.03 |
---|---|
PEG | -13.72 |
Price to Sales | 2.18 |
Price to Book Ratio | 1.6 |
Enterprise Value to Revenue | 2.36 |
Enterprise Value to EBIT | 17.19 |
Enterprise Value to Net Income | 22 |
Total Debt to Enterprise | 0.32 |
Debt to Equity | 0.58 |
No data
No data